STEMMEDICARE

Pipelines

Osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis, called a degenerative joint disease, and is a representative degenerative disease most frequently occurring in the elderly. Although many treatments and treatment technologies have been developed, they are limited to inflammatory and pain relief effects, and there is no licensed DMOAD (Disease modifying OA drug) yet. The greatest unmet need for OA treatment is to induce regeneration into hyaline cartilage, which is a normal cartilage tissue, rather than mechanically inferior fibrocartilage.

The extracellular vesicle therapeutics (MBTC-OA-EVs) developed by Stemmedicare for the treatment of osteoarthritis have proven superior to MSC treatment in promoting differentiation into chondrocytes, reducing inflammation, and protecting cartilage through in vitro assay and OA-induced animal experiments. Especially, it was confirmed that MBTC-OA-EVs have an efficacy of hyaline cartilage regeneration, which was not possible by MSC treatment until now.

MBTC-OA-EVs are being developed as various types of treatments that can minimize the discomfort of OA patients with the goal of obtaining the world's first DMOAD approval.